Stock Events

Stock Events

Chemomab Therapeutics 

$1.57
19
+$0+0% Today

Statistics

Day High
1.87
Day Low
1.47
52W High
5.88
52W Low
1.35
Volume
19,272
Avg. Volume
76,167
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9MayExpected
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.72
-0.49
-0.25
-0.02
Expected EPS
N/A
Actual EPS
-0.28

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-27.89MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CMMB. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Galapagos NV
GLPG
Mkt Cap2.09B
Galapagos NV specializes in drug discovery for fibrosis and inflammatory diseases, overlapping with Chemomab's research areas.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Madrigal Pharmaceuticals is involved in developing therapies for fibrosis and NASH, similar to Chemomab's focus areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong portfolio in liver diseases, including fibrosis and NASH, competing with Chemomab's pipeline.
Viking Therapeutics
VKTX
Mkt Cap4.3B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, directly competing with Chemomab.
Agenus
AGEN
Mkt Cap126.5M
Agenus Inc. is involved in immuno-oncology but also explores inflammatory diseases, potentially overlapping with Chemomab's therapeutic areas.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a broad portfolio that includes treatments for inflammatory diseases, indirectly competing with Chemomab in the broader market for anti-inflammatory treatments.

About

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Show more...
CEO
Dr. Adi Mor George Ph.D.
Employees
20
Country
US
ISIN
US16385C2035

Listings

F
DE
2QV.F
XNAS
US
CMMB
BOATS
BOATS
CMMB.BOATS

0 Comments

Share your thoughts

FAQ

What is Chemomab Therapeutics stock price today?▼
The current price of CMMB is $1.57 USD — it has increased by +0% in the past 24 hours. Watch Chemomab Therapeutics stock price performance more closely on the chart.
What is Chemomab Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Chemomab Therapeutics stocks are traded under the ticker CMMB.
Is Chemomab Therapeutics stock price growing?▼
CMMB stock has risen by +0.31% compared to the previous week, the month change is a -14.25% fall, over the last year Chemomab Therapeutics has showed a -61.66% decrease.
What were Chemomab Therapeutics earnings last quarter?▼
CMMB earnings for the last quarter are -0.28 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Chemomab Therapeutics revenue for the last year?▼
Chemomab Therapeutics revenue for the last year amounts to 0 USD.
What is Chemomab Therapeutics net income for the last year?▼
CMMB net income for the last year is -27.89M USD.
How many employees does Chemomab Therapeutics have?▼
As of April 01, 2026, the company has 20 employees.
In which sector is Chemomab Therapeutics located?▼
Chemomab Therapeutics operates in the Health Care sector.
When did Chemomab Therapeutics complete a stock split?▼
The last stock split for Chemomab Therapeutics was on August 26, 2025 with a ratio of 1:4.
Where is Chemomab Therapeutics headquartered?▼
Chemomab Therapeutics is headquartered in Tel Aviv, US.